FDA Accepts EYLEA® Biosimilar Application for Alvotech / Teva’s AVT06
By EsqSocial Corporation 10/03/25
On February 18, 2025, Alvotech and Teva announced the FDA acceptance of an aBLA for AVT06 (aflibercept), a proposed biosimilar of Regeneron’s EYLEA® (aflibercept). This aBLA joins Celltrion’s CT-P42 (aflibercept) awaiting FDA-approval....
By: Venable LLP